GENB
Generate Biomedicines, Inc.
Next earnings ≈ Aug 6, 2026 · est. from filing cadence
Last earnings -11.2% on 2026-05-07
$17.41
▲ +2.96%$17.41▲ +37.63%
over 1Y
L $11.21H $17.41
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+6.0%
1M+45.4%
3M+26.6%
YTD+37.6%
1Y+37.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Mixed signals in the latest filings.
Generate Biomedicines, Inc. shows limited reported revenue.
On these fundamentals, GENB screens as SELL on the SEC figures.
Is GENB a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 17.5 @ ~2.47 est
- Short put 15.5 @ ~1.47 est
debit $100max +$100max −$100BE 16.50
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Key statistics
Valuation
Enterprise value$2.23B
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗3Period ending 2026-03-022026-03-12open ↗4Period ending 2026-03-042026-03-06open ↗4Period ending 2026-02-262026-03-02open ↗4Period ending 2026-02-262026-03-02open ↗4Period ending 2026-02-262026-03-02open ↗4Period ending 2026-02-262026-03-02open ↗4Period ending 2026-02-262026-03-02open ↗4Period ending 2026-02-262026-03-02open ↗
Frequently asked
- Is Generate Biomedicines, Inc. (GENB) a buy?
- GENB currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
Sources: SEC EDGAR (CIK 0002100782, latest 10-Q filed 2026-05-07) · EODHD · as of 7/5/2026, 1:42:35 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 9:42 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.